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THE EPIGENETICS OF SMALL CELL PROSTATE 
CANCER 
Brittany North Kleb, BS 
Supervisory Professor: Ana Aparicio, MD 
Small cell prostate cancer (SCPC) is an androgen receptor (AR) negative 
variant that can develop during the progression of castration-resistant AR-
positive (AR+) prostate adenocarcinomas. While rare at initial diagnosis, SCPC is 
present in 10-20% of patients resulting in an aggressive clinical course with poor 
response to hormonal therapies and a short median survival. Our studies in 
patient-tumor derived xenografts revealed that the AR-negative small cell 
prostate carcinomas (AR-SCPC) express genes involved in neural development 
instead of the prostate luminal epithelial gene expression that characterizes AR-
positive castration-resistant adenocarcinomas (AR+ADENO). We hypothesized 
that the differences in cellular lineage programs should be reflected in distinct 
epigenetic profiles and that they could be reversed with epigenetic drugs. Using 
Methylated CpG Amplification coupled to Microarray (MCAM) we identified 
distinctly hypermethylated DNA sequences present in AR-SCPC but not in 
AR+ADENO xenografts. Because MCAM is enriched for CpG islands located 
around gene transcription start sites and it has been proposed that greater 
differences occur at CpG shores, we used the Illumina 450K platform to examine 
additional regions of the genome and we also demonstrated a strong correlation 
 vi 
 
between the xenografts’ DNA methylation profiles and the patient tumors from 
which they were derived.  
Interestingly, we observed a low frequency of AR promoter methylation 
found in samples that lacked AR expression despite previous publications. Array 
CGH analysis did not reveal copy number alterations and sequencing by others 
did not show mutations of the AR gene that could explain its silencing. We found 
that the AR promoter is enriched in silencing histone modifications (H3K27me3 
and H3K9me2) and that EZH2 inhibition with DZNep results in AR re-expression 
and growth inhibition in AR-SCPC cell lines. These data support the hypothesis 
that AR-SCPC are epigenetically distinct from AR+ADENO tumors and that 
epigenetic therapies may reverse the AR-SCPC phenotype. 
 
Keywords: castrate-resistant prostate cancer, small cell prostate cancer, DNA 
methylation profiling, methylome, histone modifications, EZH2, androgen 
receptor, epigenetics, PRC2, DZNep 
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Introduction 
Prostate Cancer 
Prostate cancer (PCa) is the most common malignancy in males with an 
estimated 233,000 new cases diagnosed in 2014 the United States with 29,480 
deaths due to the disease [American Cancer Society, 2014]. Prostate tumors are 
clinically heterogeneous, where some patients die of metastatic disease within 2–
3 years of diagnosis while others can live for 10–20 years with organ-confined 
disease [1]. The wide range of survival outcomes is observed due to the 
underlying biological heterogeneity of the disease. A better understanding of the 
drivers of disease progression in each subset will lead to implementation of 
specific therapies for each subset improving overall patient survival. Castration 
remains the most effective way to control the disease and continues to be the 
first line of treatment, however, the majority of deaths are due to resistance to 
this therapy regimen. Currently the clinical model of prostate cancer progression 
is defined by pathological classifications where morphological features of the 
tumor determine a Gleason sum score [2]. These resulting scores group patients 
into clinical stages and ultimately determine treatment plans. A Gleason score is 
also an important prognostic determinate where high scores predict more rapid 
progression and aggressive treatments [3]. While Gleason scores and staging 
are important in early treatment decisions, as the disease progresses the clinical 
management of CRPC is limited. All CRPCs are treated the same even though 
the tumors behave very different. Molecular classification and resulting molecular 
 2 
 
markers of progression are necessary for proper diagnosis and treatment of this 
disease. 
 
AR Centered Disease 
The androgen receptor is a ligand dependent transcription factor. It 
resides in the cytoplasm as a protein complex composed of heat shock proteins 
in a ligand free, inactive state. Activation of the AR is dependent on androgen 
signaling. Circulating testosterone enters the prostate cell, where it is converted 
to dihydrotestosterone (DHT) by the enzyme 5a-reductase. Activation of the 
androgen receptor occurs through the binding of DHT resulting in a 
conformational change. This leads to dissociation from the heat shock proteins, 
receptor phosphorylation and the formation of a homodimer complex.  This 
homodimer complex then travels to the nucleus where is can bind to androgen 
response elements on target genes to recruit co-regulatory proteins, co-
activators or co-repressors triggering transcriptional activation or repression of 
various genes.  Its ability to regulate genes that both stimulate proliferation and 
inhibit apoptosis through androgen stimulation makes AR important in the growth 
and survival of prostate cancer cells. 
Therefore, prostate cancer depends on a crucial level of androgenic 
stimulation and androgen ablation is the primary therapy for prostate cancer. 
Prostate cancer can progress following castration (CRPC) and most remain 
sensitive to secondary hormone therapies due to the activity of the androgen 
receptor [4, 5]. However, approximately 20% of men who die of CRPC have 
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tumors with small cell carcinoma morphology, a variant that loses AR expression, 
is resistant to hormonal therapies [6], and predicts for a poor clinical outcome [7, 
8].  
 
Molecular Classification of Prostate Cancer 
The molecular mechanisms of prostate cancer progression have been 
centered on the androgen receptor, the tumor microenvironment, oncogenes and 
tumor suppressors. Loss of tumor suppressor genes PTEN, p53, and RB is 
critical and common in prostate cancer progression. The loss of PTEN results in 
the upregulation of the PI3K pathway and frequently observed in metastatic 
disease. Its loss is also linked to shorter progression-free and overall survival but 
not a predictive measure of response to specific therapies [9, 10]. The tumor 
suppressor RB is known to protect against tumor development through the 
suppression of cell cycle progression genes. The loss of RB is linked to more 
advanced stages of CRPC, and could be used as a predictive marker of 
response to therapies [11]. However, the role of RB in castration resistant 
disease transition from AR positive to small cell phenotype is not well 
established, although their response to chemotherapy could be due to RB loss. 
Aberrant activation of oncogenes is prevalent in the late stage of prostate 
cancer progression, including Src, MET, Axl, and FGFR. The most frequent 
oncogenic event in prostate cancer is the TMPRSS2:ERG gene fusion resulting 
in overexpression of the ERG gene, a transcription factor that regulates cellular 
proliferation and PI3K pathway activation [12, 13]. Additionally this gene fusion 
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does not correlate with adverse tumor characteristics or poor prognosis. [14] In 
fact TMPRESS2:ERG is associated with low grade disease [15]. AR negatively 
regulates the oncogene c-Met and therefore with androgen ablation, overtime the 
MET receptor is overexpressed triggering tumor growth and blood vessel 
formation [16]. The non-receptor tyrosine kinase, c-Src, regulates a complex 
signaling network that drives the development of castrate resistance through 
multiple biological processes. Inhibitors of this pathway have been used in 
clinical trials and shown efficacious in limited subset of tumors. The activation of 
oncogenic pathways also affects AR function through AR phosphorylation or 
direct association of the receptor [17, 18]. 
 
SCPC 
Along with small cell morphological features, SCPC also displays distinct 
clinical characteristics including frequent visceral metastases, lytic bone 
involvement, relatively low PSA, resistance to androgen ablation therapy, and 
high response rates to chemotherapy [8]. SCPC is a rare finding at the time of 
initial prostate cancer diagnosis and most frequently found during the castration 
resistant progression of the disease mixed with adenocarcinoma components 
[19]. This unique clinical phenotype can be observed in the absence of small cell 
carcinoma morphology but that it maintains its specific molecular profile: loss of 
tumor suppressors (pRb, p53), switch from epithelial to neural progenitor/stem 
cell program and aberrant mitotic gene expression [3, 20, 21]. There is a marked 
increase in mitotic genes, especially M-phase transition genes, including AURKA, 
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PLK1 and UBE2C [22]. Histopathological evaluation of these mixed tumor 
specimens display what appears to be a gradual transition from the 
adenocarcinoma to the SCPC component [11]. In addition, several groups have 
shown concordance in the ERG rearrangements present in the morphologically 
distinct components of the same tumor [9, 23] suggesting that both arise from a 
common cell of origin. SCPCs lose features of the luminal prostate epithelium 
and adopt a neural precursor phenotype with increased levels of pro-neural 
transcription factor expression including ASCL1 and MYCN [20, 21, 24-27]. 
MYCN is highly expressed in early embryogenesis and in cancers that originate 
from embryonic or neuroendocrine tissues such as small cell lung cancer [27], 
suggesting SCPCs have a neural developmental program [28]. Therefore, the 
molecular switch from epithelial to neural/progenitor stem cell program occurs 
through a transdifferentiational switch, implicating an underlying epigenetic 
mechanism might exist.  
 
Prostate Cancer Epigenetics 
Epigenetics refers to functionally relevant genomic information not coded 
by the DNA sequence and heritable during cellular division. There are multiple 
epigenetic modifications that contribute to the initiation and progression of 
prostate cancer including DNA methylation, histone modifications, microRNAs, 
long noncoding RNAs, and post translational modifications. 
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DNA Methylation 
Methylation of DNA cytosine residues that precede guanine (CpG) is 
tightly associated with gene regulation and occurs in short stretches of CpG-rich 
regions found in the promoters of about 60% of genes [29]. These CpG rich 
regions are known as CpG islands (CGIs) and are generally unmethylated in 
normal cells. However, in cancer cells, aberrant hypermethylation, a gain of 
methylation, occurs in promoter CGIs resulting in gene silencing and loss of 
function [30]. Conversely, global hypomethylation is commonly observed in 
tumors resulting in genomic instability through the resultant change in chromatin 
structure.  DNA methylation profiling of CRPC could expose key subset of genes 
modified and used as markers or reveal an underlying biological mechanism of 
the disease. A list of promoter methylation at the single gene level has been 
reported in prostate cancer, including GSTPI, AR, APC, RASSF1, and CDH1 
with functional consequences.  There are very few studies investigating the 
epigenomic landscape of CRPC. In 2004, Yegnasubramanian et al. reported on 
the methylation of 16 promoter CpG islands in 83 metastatic samples obtained at 
autopsy from 28 men who had been treated with androgen-deprivation therapy 
[31]. Those investigators also observed that CRPC metastatic sites had 
significantly lower levels of 5-methylcytosine and of long interspersed elements 1 
(LINE1) methylation, a marker of global methylation, than did the primary and 
untreated prostate cancer tissues, and they found decreased methylation in the 
promoter CGIs of a group of cancer–testis genes in metastatic tissues [31, 32].  
In subsequent studies, a very similar methylation pattern in primary and 
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metastatic prostate cancer tissues that was maintained across metastatic sites 
within a patient, but methylation patterns in different patients appeared 
heterogeneous [33]. However, those findings did not appear to hold true in the 
AR– prostate cancer cell lines PC-3 and DU145, and again, the between-patient 
heterogeneity appeared greater than that within given patients. Another study 
profiled the DNA methylome of 15 liver and soft tissue metastatic CRPC samples 
obtained at autopsy and observed three of their 15 samples with a 
hypomethylated phenotype relative to that of the rest [34]. Of these previous 
studies, the investigators were unable to show significant correlation with 
clinicopathologic or molecular features within the samples [33, 34].  
Therefore, we hypothesized DNA methylation could thus be used to 
classify CRPC into clinically relevant predictive subgroups, performing genome-
wide DNA methylation profiling of 34 human prostate cancer xenografts obtained 
from 24 castrate patients, using methylated CpG amplification coupled to 
microarray (MCAM) analysis. We identified distinctly hypermethylated DNA 
sequences in AR-SCPC versus AR+ADENO xenografts. Because MCAM is 
enriched for CpG islands located around gene transcription start sites we used 
the Illumina 450K platform to examine additional regions of the genome and to 
demonstrate correlation between the xenografts’ DNA methylation profiles and 
the patient tumors from which they were derived. We focused on site-specific 
DNA methylation at the AR CpG island. There was a low frequency of AR 
promoter methylation found in samples that lacked AR expression. We continued 
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our investigation of the AR promoter region by evaluating the histone 
modification patterns. 
 
Histone Modifications & EZH2 
In eukaryotes, DNA is packaged by winding itself around repeating units of 
nucleosomes composed of histone protein complexes. The nucleosome is 
comprised of 147 base pairs of DNA wrapped around an octamer of histones (2 
each of H2A, H2B, H3, and H4). Nucleosomes are then coiled into higher order 
structures to allow for chromatin compaction and are essential for gene 
regulation. The local structure of the chromatin influences DNA accessibility and 
determines distinct patterns of gene expression. Open chromatin allows for the 
recognition of specific DNA sequences by transcription factors, enhancers, and 
polymerases essential for gene transcription whereas closed chromatin restricts 
access to the DNA. There are two mechanisms that control the accessibility of 
chromatin and subsequent gene transcription—displacement of histones by 
chromatin remodeling complexes and enzymatic modifications to histones. Post-
translational modifications to the histones include the addition or removal of 
acetyl, methyl, phosphate, or ubiquitin groups to the amino-terminal tails histone 
tails. Each modification affects the chromatin in different ways by either recruiting 
regulatory proteins or altering the structural components of the chromatin. Lysine 
methylation is predominately used to regulate chromatin structure with the 
addition of three methyl groups on H3 lysine 4 (H3K4me3) resulting in open 
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chromatin and active gene expression and the contrasting tri-methylation of H3 
lysine 27 (H3K27me3) produces closed chromatin and gene suppression.  
A class of proteins that control the chromatin organization are the 
Polycomb group (PcG) proteins. They function as key epigenetic regulators of 
gene transcription through multimertic complexes catalyzing the covalent 
additions to the histone tails and writing the histone code. These proteins were 
originally discovered as repressors of a family of developmental genes, the 
homeodomain-containing transcription factors (Hox) in Drosophila melanogaster 
and essential in normal mammalian development [35]. They comprise two 
distinct Polycomb repressive complexes (PRC1 and PRC2) functioning together 
to maintain long term silencing [35]. One such cooperation includes the 
trimethylation of H3K27 by PRC2 mediates the recruitment of PRC1 to the gene 
loci to elicit further consolidation of the condensed chromatin. Enhancer of zeste 
homolog 2 (EZH2) is the protein necessary for the catalytic function of PRC2 
complex with its SET domain as the active site for the methylation reaction. In 
order for EZH2 to function enzymatically, two other proteins must also be 
involved, embryonic ectoderm development (EED) and suppressor of zeste 12 
(SUZ12).  These three proteins along with two histone binding proteins 
retinoblastoma binding protein 4 and 7 (RBBP4 and RBBP7) make up the core 
components of PRC2 [36]. Overexpression of EZH2 has been shown in multiple 
solid tumors including breast, bladder, gastric, and prostate cancer [37-40]. It 
was first associated with prostate cancer in 2002 by a cDNA microarray study 
demonstrating its upregulation prominently in metastatic prostate cancer as 
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compared to localized disease [38]. Additionally, the results indicated a positive 
relationship between EZH2 protein level and disease aggressiveness [38]. Global 
upregulation of EZH2 could result in increased H3K27me3 at key tumor 
suppressor gene loci. Therefore we challenged that EZH2 mediated H3K27me3 
could play a role in the AR gene silencing of the AR-SCPC. Using ChIP q-PCR 
we observed enrichment in H3K27me3 at the AR promoter region in our AR- 
samples suggesting a possible mechanism of AR silencing in SCPC.  
 
Noncoding RNAs 
Noncoding RNAs (ncRNAs) are endogenously transcribed RNA that do 
not result in protein translation, but function in an epigenetic fashion to control 
gene expression and protein function. Several ncRNAs are abbarently expressed 
in prostate cancer. MicroRNAs (miRNAs) function as translational silencers by 
binding to the target gene’s transcribed mRNA and degrading it. Genomic loss of 
microRNA-101 leads to the overexpression of EZH2 predominately in more 
aggressive prostate cancers than in localized disease [41]. Additionally long 
noncoding RNAs (lncRNAs), ncRNAs >200 nucleotides, have been implicated in 
epigenetic manipulation of gene expression in prostate cancer with both 
oncogenic and tumor suppressor effects [42]. Interestingly, the lncRNA ANRIL 
supplies two layers of epigenetic regulation of the tumor suppressor p15 by 
interacting with SUZ12, recruiting PRC2 to the gene loci and silencing the gene 
in CRPC [43]. 
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Due to the unique way epigenetic alterations control the transcriptional 
machinery of a gene without disrupting the DNA sequence, they have the 
potential to be reversed. Therefore inhibitors have been developed to disrupt 
epigenetic silencing and used as tools to study the biology of diseases along with 
pharmacological potential. One such molecule, 3-deazaneplanocin-A (DZNep), 
was developed as a potent inhibitor of S-adenosyl-Lhomocysteine (SAH)-
hydrolase, an EZH2 cofactor, and depletes cellular levels of the PRC2 complex 
resulting in the inhibition of H3K27me3 [44, 45]. We used DZNep as a tool to 
manipulate SCPC in vitro and reveal a surprising epigenetic feature of the 
disease. 
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Results 
Xenograft and Donor Patient Features 
For the MCAM studies, we analyzed DNA extracted from mouse 
subcutaneous tissue, cultured PrECs and from 34 human prostate cancer 
xenograft tissues derived from the tumors of 24 patients. The MDA 79, MDA 117, 
MDA 118b, MDA 144, MDA 146 and MDA 155 xenograft lines and sublines have 
been previously described [20, 21]. Of the 34 samples, 14 included 2 to 6 
xenograft sublines derived from the same donor tumor (eg, 146.10 to 146.12) 
and 2 biologic replicates (ie, the same xenograft subline but grown in a different 
mouse; eg, 144-4R) (Table 1). 
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Eleven of the 34 samples displayed SCPC morphology, 1 showed mixed ADENO 
and SCPC features and 3 had large cell neuroendocrine (LCNEC) morphology. 
LCNEC is a rare variant that bears strong similarities with SCPC and is thought 
to represent a transitional form between ADENO and SCPC [21]. Additional AR-
negative samples included one with squamous cell carcinoma morphology and 
Patient 
Donor 
Xenograft         
Line-Subline
DMSO 
or FF
DNA 
Quantity (ug)
260/280 
Ratio
DNA-EP 
Smear Morphology
AR 
(%cells)
% Mouse 
DNA Avg
% Mouse 
DNA SD
31 MDA-31 D 828 1.94 ADCA 85±5 1.11 0.00
40 MDA-40 D 435 1.97 ADCA 0±0 1.19 0.22
43 MDA-43 D 1596 1.98 ADCA 80±0 1.30 0.25
44 MDA-44 D 369 1.88 SCPC 0±0 2.00 1.16
46 MDA-46 D 654 1.89 - - 0.71 0.26
51 MDA-51 D 229 1.94 ADCA 0±0 6.83 0.46
62 MDA-62 D 570 1.93 Mixed ADCA & SARC 0±0 37.15 14.73
66 MDA-66 D 289 1.94 ADCA 0±0 3.79 3.69
75 MDA-75 D 51 1.96 ADCA 90±0 1.54 0.05
76 MDA-76 D 1250 1.90 Yes ADCA 86±12 14.47 3.02
79 MDA-79 D 522 1.92 Yes ADCA 89±6 57.41 51.61
80 MDA-80 D 111 1.94 ADCA 90±4 0.97 0.06
MDA-91A D 450 1.96 SCPC 0±0 1.92 0.67
MDA-91B D 704 1.89 SCPC 0±0 1.69 0.00
94 MDA-94 D 277 1.96 ADCA 0±0 3.56 2.81
100 MDA-100 D 190 1.93 SQ CELL CA 0±0 9.32 3.10
101 MDA-101 D 1422 1.94 Yes ADCA 63±20 7.92 4.11
102 MDA-102 D 909 1.93 Yes - - 12.84 6.87
117 MDA-117-9 FF 554 1.90 ADCA 96±2 1.28 0.41
118 MDA-118b FF 308 1.91 ADCA 0±0 57.38 21.00
122 MDA-122 FF 880 1.97 ADCA 90±0 11.58 2.89
137 MDA-137 FF 763 1.89 ADCA 100±0 10.64 1.69
MDA-144-11 FF 540 1.94 SCPC 0±0 5.07 0.28
MDA-144-13 FF 576 1.95 SCPC 0±0 1.84 0.32
MDA-144-13R FF 876 1.89 SCPC 0±0 1.69 0.60
MDA-144-20 FF 1415 1.98 SCPC 0±0 0.78 0.05
MDA-144-23 FF 831 1.96 SCPC 0±0 1.24 0.03
MDA-144-4 FF 1122 1.98 LCNEC 0±0 1.51 0.03
MDA-144-4R FF 808 1.92 LCNEC 0±0 1.16 0.78
MDA-144-6 FF 1398 1.95 LCNEC 1±2 2.53 2.60
MDA-146-10 FF 970 1.91 SCPC 0±0 0.66 0.53
MDA-146-12 FF 1051 2.04 Mixed ADCA & SCPC 97±6 3.35 0.28
MDA-155-12 FF 884 1.95 SCPC 0±0 1.01 0.01
MDA-155-2 FF 1132 1.96 SCPC 0±0 1.35 0.36
Abbreviations: MDA, MD Anderson; DMSO or D, stored in dimethyl sulfoxide; FF, fresh frozen; EP, electrophoresis; ADCA, 
adenocarcinoma; SCPC, small cell prostate carcinoma; SARC, sarcomatoid; SQ CELL CA, squamous cell carcinoma; LCNEC, large 
cell neuroendocrine carcinoma; AR, androgen receptor.
 Table 1. Xenograft Sample Description.
91
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another with mixed adenocarcinoma and sarcomatoid features. Paraffin 
embedded tissues were not available for xenografts MDA 102 and MDA 46, 
morphology unknown. The remaining 13 samples had ADENO morphology but 5 
of these did not express AR by immunohistochemistry. Four DNA samples 
exhibited a smear on gel electrophoresis, indicating significant DNA degradation; 
however, a strong high molecular–weight band was still present in all 4. Seven 
samples had >10% mouse DNA contamination (Table 1; Figure 1). Neither DNA	   
degradation nor mouse DNA contamination affected the quality of the arrays. The 
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Figure 1. Percent Mouse DNA. The amount of mouse DNA contamination found 
in xenografts detected by quantitative PCR using the Human and Mouse beta 
globin gene expression. 
Percent of Mouse DNA Contamination 
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charts of the 24 donor patients (4 of whose tumors yielded >1 xenograft line) 
were retrospectively reviewed (Table 2). All patients had received ADT, and 20 
had received at least 1 line of chemotherapy (often containing more than 1 
agent) before xenograft establishment. One patient (the donor of MDA-43) 
remains alive, 16.1 years after diagnosis following bilateral adrenalectomy.    
 
DNA Methylation Profiles of Patient Tumor Derived Castration Resistant Prostate 
Cancer Xenografts  
Unsupervised hierarchical clustering (Ward linkage, Euclidean distance) 
using all M values for the 16,621 SmaI sites after LOWESS normalization 
showed that for the most part, the xenograft lines derived from the same patient 
clustered together (Figure 2): Only two of the MDA 144 (MDA 144-20 and MDA	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31 MDA-31 W 55 Liver - No No 2.4 1 0.7 3.0 2.8 1.1 0.4
40 MDA-40 W 65 Liver 18.5 No Yes 1.5 2 0.2 4.7 1.7 0.3 0.2
43 MDA-43 B 61 Adrenal 66.7 Yes No 2.3 0 - 16.4 16.1 - 13.9
44 MDA-44 W 61 SQ nodule - Yes Yes 6.1 2 1.2 6.4 6.4 1.5 0.3
46 MDA-46 W 53 Pleural fluid 32.0 No Yes 3.0 2 1.8 4.2 3.3 2.1 0.3
51 MDA-51 W 83 Liver 13858.0 Yes No 2.6 0 - 3.9 3.8 0.7 1.2
62 MDA-62 W 59 Ascitic fluid 5.3 No No 0.3 3 0.3 1.9 0.4 0.3 0.0
66 MDA-66 W 53 Pelvic tumor 18.4 - Yes 5.1 2 1.7 8.4 7.3 3.8 2.1
75 MDA-75 B 66 Brain 6.2 No - 4.4 0 - 5.5 4.5 - 0.1
76 MDA-76 W 64 Pelvic tumor 173.0 No No 2.6 2 0.9 3.2 2.8 1.2 0.3
79 MDA-79 W 60 Pelvic tumor 65.0 - Yes 6.2 2 0.9 13.1 11.9 6.6 5.7
80 MDA-80 W 67 Pleural fluid 234.0 Yes Yes 2.5 3 1.2 3.1 3.1 1.8 0.6
91 MDA-91 W 37 Liver 42.0 Yes Yes 4.8 3 4.2 6.9 6.8 6.2 2.0
94 MDA-94 W 61 Pleural fluid 4.1 Yes Yes 3.4 3 2.1 4.2 4.1 2.8 0.7
100 MDA-100 W 69 Pelvic tumor 0.9 No No 1.0 4 1.0 4.1 4.1 4.1 3.1
101 MDA-101 W 67 Liver 6.4 No Yes 1.3 2 0.8 3.9 1.7 1.2 0.4
102 MDA-102 W 61 Pelvic tumor 12.3 No Yes 6.6 1 0.7 14.7 12.0 6.2 5.4
117 MDA-117 H 59 Pelvic tumor 99.2 - Yes 4.3 1 0.4 5.2 5.2 1.3 0.9
118 MDA-118b W 47 Bone 5180.0 Yes Yes 1.6 2 0.4 1.9 1.9 0.7 0.3
122 MDA-122 W 60 Adrenal 7.6 No - 5.1 0 - 14.4 7.6 - 2.5
137 MDA-137 W 56 RPLN 13.5 No Yes 6.0 2 0.7 8.0 6.5 1.2 0.6
144 MDA-144 W 67 Pelvic tumor na No No 1.1 2 0.7 4.7 1.4 1.0 0.3
146 MDA-146 W 73 Pelvic tumor 10.7 No No 1.2 1 0.3 6.1 2.5 1.6 1.3
155 MDA-155 W 72 Pelvic tumor 4.6 Yes Yes 0.4 2 0.4 0.6 0.6 0.6 0.2
Table 2. Clinical Characteristics of Donor Patients.
Abbreviations: W, white; B, black; H, hispanic; SQ, subcutaneous; RPLN, retroperitoneal lymph node; PSA, prostate specific antigen; ADT, androgen 
deprivation therapy; y, years; Chemo, chemotherapy; Pre-X, prior to xenograft development; OS, overall survival.
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144-11) sublines did not cluster with the other 6 MDA 144 samples. All other 
xenograft sublines derived from a single patient tumor clustered together (MDA 
146-10 with MDA 146-12, MDA 155-12 with MDA 155-2, MDA 91A with MDA 
91B). This suggests that the misclassification of the MDA 144-20 and MDA 144-
11 sublines might be due to methodological differences and supports the notion 
that DNA methylomes are stable in xenografts. To validate the MCAM results, we 
selected 19 sequences contained within 17 promoter-associated (± 1 kb from 
closest TSS) CGIs for Pyrosequencing. Using 10% as the cutoff for calling a 
sequence hypermethylated and a normalized log2 ratio of tumor:normal signal 
≥1.3, we obtained a sensitivity of 89.8%, a specificity of 67.0%, a positive 
predictive value of 71.0% and a negative predictive value of 87.9% (Figure 3), 
consistent with our previous experience with the MCAM method [46].  
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Figure 2. Unsupervised hierarchal clustering. Unsupervised hierarchical 
clustering (Ward linkage, Euclidean distance) using all M values for the 
16,621 SmaI sites after LOWESS normalization    
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In later analyses, we excluded 1,800 SmaI sites to account for nonspecific 
hybridization of contaminant mouse DNA in the xenograft DNA samples and for 
Figure 3. Methylated CpG-island Amplification coupled to CpG island 
microarray (MCAM) validation. Pyrosequencing was used to measure the % 
DNA methylation of 19 randomly selected sequences (Sma I sites) contained 
within 17 promoter-associated CpG islands (Genes) in the xenograft samples 
and in the pooled DNA from normal male volunteer peripheral blood 
mononuclear cells (PBMC). Shown in the y-axis is the % DNA methylation in 
the xenograft samples minus the % DNA methylation in the pooled normal 
DNA (% Methylation Xenograft-Normal). Shown in the x-axis are the MCAM M 
values (normalized log
2 
ratio of xenograft:normal PBMC fluorescent signal). 
Sequences with M values ≥ 1.3 and % DNA methylation by Pyrosequencing 
>10% were considered hypermethylated. The number of true negative 
(n=175), true positive (n=211), false negative (n=86) and false positive (n=34) 
values are shown in each quadrant and used to calculate the specificity, 
sensitivity, positive predictive value (PPV) and negative predictive value 
(NPV).  
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tissue-specific hypermethylation of prostate cells, compared with normal blood 
(1,317 from mouse DNA, 553 from PrEC DNA and 70 from both) leaving a total 
of 14,821 SmaI fragments for analysis. We averaged the log2 ratio values of 
technical and biologic replicates of the same tumors and, with the 1.3 cutoff, 
found that the frequency of hypermethylated SmaI fragments ranged from 2.2% 
to 12.7% (median, 6.6%) per xenograft (Figure 4A). However, 80% of the studied  
SmaI fragments were unmethylated across all samples, and correlated 
hypermethylation was rare, with only 527 of 14,821 SmaI fragments (3.5%) being 
hypermethylated in 50% or more of the tumors.  
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We classified the 14,821 SmaI fragments according to their relationship to 
the promoter region of known RefSeq genes and with CpG islands and examined 
the frequency of hypermethylation in each compartment. The first clear 
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Figure 4. Methylation 
Frequency A. Frequency of 
methylation by SmaI fragments 
across all CRPC xenografts B. 
Frequency of hypermethylated 
SmaI fragments across all CRPC 
xenografts, in total and 
subdivided according to their 
relationship to the transcription 
start site (TSS) of known RefSeq 
genes and CpG islands (CGI). C. 
Frequency of hypermethylated 
SmaI fragments per patient 
(results averaged if multiple 
xenograft sublines available for a 
given patient), in total and 
subdivided as in B. 	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observation was that the compartment consisting of nonpromoter CpG islands is 
generally 2 to 3 times more hypermethylated than any other compartment is and 
that promoters associated with CpG islands constitute the least-hypermethylated 
compartment (Figure 4B).  Figure 4C is a more detailed presentation of the 
fractions of hypermethylated SmaI sites in each compartment in the different 
xenograft lines. In general, there was good agreement: xenograft lines with the 
lowest frequencies of methylated promoter CpG islands, for example, also had 
very low frequencies of hypermethylated nonpromoter CpG islands, non-CpG 
island promoters, and nonpromoter non-CpG island SmaI sites. 
 
DNA methylation markers distinguish AR+ from AR– CRPC tumors  
To determine whether DNA methylation markers could distinguish the AR+ 
from the AR– xenografts, we used the averaged probe M values per patient 
converted to categorical values (log2R/G≥1.3 = methylated, log2R/G<1.3 = 
unmethylated) and focused only on promoter CpG islands, because this is the 
compartment that has been shown to be associated with a clear biologic 
consequence: silencing of the associated gene [47]. Using Student’s t test we 
found thirty-two gene promoter CpG islands that displayed statistically significant 
different frequencies of hypermethylation between AR+ and AR– xenografts 
(Figure 5A; P < 0.01). Of these, pyrosequencing analysis confirmed the 
differential methylation of 4 of 5 randomly chosen gene promoter CpG islands: 
CNN3, GAS6, SOX8, and MAP6 (Figure 5B). Two of these 4 (CNN3 and GAS6) 
were also found to be differentially methylated by pyrosequencing in a small set 
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of DNA samples obtained from 5 AR+ and 4 AR– patients’ tumor samples that 
were unrelated to the xenografts (Figure 5B).  
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Figure 5. DNA Methylation Markers A. Gene promoter CpG islands 
differentially methylated between AR
+ 
and AR
-
 xenografts. B. Validation by 
pyrosequencing in DNA extracted from xenograft tumors. C. Validation by 
pyrosequencing in DNA extracted from 9 unrelated patient tumors.  
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Differential DNA Methylation Markers Between AR-SCPC and AR+ADENO 
Xenografts 
To determine whether DNA methylation markers distinguished AR-SCPC from 
AR+ADENO we excluded samples with ADENO morphology that did not express 
AR (MDA 40, MDA-51, MDA 62, MDA 66, MDA 94 and MDA 118b), the 
xenograft with squamous cell morphology (MDA 100), the xenografts for which 
morphology was unknown (MDA-102 and MDA-46) and the “misclassified” MDA 
144-20 and MDA 144-11 sublines. This left 9 AR-SCPC and 3 AR-LCNEC 
(previously found to be biologically similar to AR-SCPC [21]) xenograft samples 
(n=12) plus 1 mixed AR-SCPC and AR+ADENO derived from 5 patient donor 
tumors and 10 AR+ADENO xenograft samples derived from 10 patient donor 
tumors. Unsupervised hierarchical clustering using the top 10 percent 
hypervariable probes of the 14,821 SmaI sites (as described above) from the 
averaged probe M values per patient converted to categorical values 
(log2R/G≥1.3 = methylated, log2R/G<1.3 = unmethylated) showed separate 
clusters (with the exception of two xenografts, 79 and 101) that distinguishes the 
AR-SCPC and AR+ADENO morphological groups (Figure 6). Additionally, a 
Student’s t test was performed to determine candidate genes that stratify these 
groups. There were 250 genes with a p-value<0.01. From these, we chose 10 
genes based on gene function and validation with data gathered in the Illumina 
Infinium Methylation 450k Beadchips (see data below). These genes will be used 
for future validation on patient samples (RCCD1, IGF2BP1, TMPRSS2, LPHN1, 
HAND2, KCNV1, PDE1C, PROKR2, KIRREL, HOXD4). 
 23 
 
 
 
Figure 6. Differential DNA Methylation Markers 
Between AR
-
SCPC and AR
+
ADENO Xenografts. 
Unsupervised hierarchical clustering using the top 10% 
hypervariable probes of the averaged probe M values per 
patient converted to categorical values (log2R/G≥1.3 = 
methylated, log2R/G<1.3 = unmethylated). 
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Xenografts Reflect Patient Donor Methylation Patterns 
To compare global methylation of primary patient tissues to matched 
xenograft tissues and the stability of the methylome after tumor passage from 
human to mouse, we employed the Illumina Infinium Methylation 450k Beadchips 
(Illumina, San Diego, CA) platform. Patient donor tumor DNA was available for 
xenografts MDA 144-4, MDA 146-10, MDA 150-10, MDA 153-14, MDA 170-1 
and MDA 180-14. DNA from MDA 144-4 and MDA 146-10 were analyzed by 
MCAM as above (Table 1). Xenografts MDA 170-1 and MDA 180-14 have been 
described previously	   [20]. The Infinium methylation array provides 
comprehensive coverage of the gene including six areas around the CpG 
island—north shelf (flanking upstream of shore), north shore (flanking upstream 
of island), island, south shore (flanking downstream of island), south shelf 
(flanking downstream of shore), and no island. These areas are in relation to 
known UCSC CpG islands and cover gene regions with sites in the promoter 
region, 5’UTR, first exon, gene body, and 3’UTR. We evaluated the frequency of 
methylation changes, referring to a significant methylation increase as 20% 
greater than the primary sample and significant methylation decrease as 20% 
greater than the primary sample, between the xenografts and matched patient 
samples within these regions (Figure 7A).  We observed a higher frequency in 
hypomethylation among the xenograft samples as compared to their patient 
donor with the highest in the 180-30 (Figure 7B). Overall, frequencies of 
significant methylation changes, for the most part, were below 10%, therefore, 
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we feel the xenografts retain the methylation patterns to that of their patient 
primary sample. 
 
AR Promoter Methylation Is Rare in CRPC 
A large CpG island spans the promoter and exon 1 of the androgen 
receptor gene and previous reports have shown DNA hypermethylation in this 
region resulting in AR gene silencing in prostate cancer cells. [48, 49]  Our 
previous work had shown that both the AR protein and mRNA transcripts were 
absent in our AR-SCPC models and array CGH experiments did not reveal AR 
deletions.[20] We were struck by the low levels of methylation observed in the 
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Figure 7. Frequency of Methylation Changes Between Xenograft and 
Patient. The frequency of methylation changes between xenograft and 
primary patient samples using the Illumina Infinium Methylation 450k 
Beadchips. A. The frequency represents the average percentage of probes 
with 20% more methylation in the xenograft than the patient (light grey 
bars) and the average percentage of probes among all patients with 20% 
less methylation in the xenograft than the patient (dark grey bars) broken 
down by island regions.  The schematic below the graph depicts the 
location of the regions as compared to the CpG island (lollipop figures 
represent CpG sites). B. The frequency of methylation changes by patient. 
The light grey bars represent the frequency of methylation increases by 
20%, while the dark grey bars represent the frequency of methylation 
decreases by 20%. 
B. A. 
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AR promoter of the AR-SCPC xenografts. Therefore, we examined the 
methylation of the AR promoter-associated CpG island using bisulfite 
pyrosequening (Figure 8A) in DNA extracted from 11 AR+ and 19 AR- patient 
derived xenografts, a xenograft derived cell line [144.13c], as well as the prostate 
cancer cell lines LNCaP, PC3, NCI H660 and DU145. Of the cell lines, only PC3 
and DU145, have more than 15% methylation, confirming what others have 
reported [31]. All but 4 of the xenografts had less than 15% methylation at the AR 
promoter regardless of AR expression status (Figure 8B). Our results indicate 
DNA methylation of the AR promoter is infrequent in CRPC. 
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H3K27me3 is Enriched at the AR promoter in AR-SCPC Xenografts 
We then examined the chromatin markings on the AR promoter using 
ChIP-qPCR in the previously described AR-SCPC/LCNEC (MDA PCa 144.13, 
MDA PCa 144.4, MDA PCa 155.2 and MDA PCa 146.10) and AR+ADENO (MDA 
PCa 170.4 and MDA PCa 180.30) xenografts [20, 21]) as well as in three 
established prostate cancer cell lines (one AR-positive [LNCaP] and two AR-
negative [PC3 and DU145]). We evaluated both active, H3K4me3 and H3K9ac, 
and repressive H3K9me2 and H3K27me3 histone modifications using the 
marking of the constitutively expressed gene Actinβ (ACTB) and a repressed 
gene in prostate tissue, Human β-globin (HBB), as controls for these 
experiments. As expected, the only samples with AR marking by H3K4me3 
and/or H3K9ac were the two AR-positive xenografts MDA PCa 170.4 and MDA 
PCa 180.30 and LNCaP. Marking by repressive histone modifications was more 
variable: H3K27me3 was a universal finding in AR-negative samples, and was 
accompanied by H3K9me2 in two out of four xenografts (Figure 9). 
It is important to note that DU145 and PC3 both have marked enrichment 
of H3K27me3 and H3K9me2 along with high promoter methylation.  Previous 
reports have shown that there is a strong correlation between H3K9me2 and 
DNA methylation.  In contrast, H3K27me3 based silencing is independent of 
DNA methylation and some genes in the PC3 cell line are targeted by both 
silencing mechanisms, but this seems to be a rare observation. [50] 
Consequently, we focused on H3K27me3 as the possible mechanism for AR 
silencing in SCPC.   
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Global EZH2 and H3K27me3 levels did not appear different between AR-SCPC 
and AR+ADENO models  
H3K27me3 gene silencing involves polycomb group protein EZH2 which 
correlates with the aggressiveness of prostate cancer and is known to be 
overexpressed in multiple cancers [38]. We therefore looked at the global protein 
expression of H3K27me3 and EZH2 in our xenograft samples and cell lines. 
Using western blot analysis, we observed similar levels of global protein 
expression of both H3K27me3 and EZH2 in the AR- xenografts and cell lines as 
compared to the AR+ xenograft (Figure 10).  
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DZNep treatment induces AR expression in AR-SCPC cell lines 
To confirm H3K27me3 based silencing of the AR promoter in SCPC, we 
evaluated whether inhibition of EZH2 methyltransferase activity could result in 
AR reexpression. We used DZNep, a known S-adenosylhomocysteine (AdoHcy) 
hydrolase inhibitor, which leads to the indirect inhibition of methyltransferase 
activity by blocking S-adenosyl-methionine (AdoMet) dependent reactions. [44] 
Previous reports have shown a correlation between a decrease in H3K27me3 by 
DZNep treatment and an increase of gene expression. [44] We treated two AR- 
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SCPC cell lines, NCI H660 and 144.13, with 0.1, 1 and 5 uM DZNep for 72 hours 
and evaluated AR expression following treatment by qPCR (Figure 11A). We 
observed a trend toward increase AR mRNA expression in both 144-13 and NCI 
H660 cell lines with 1 and 5 uM DZnep treatment. Although we did not see a 
statistically significant increase in AR transcript levels following treatment, we 
tested whether the slight increase resulted in protein translation. Using western 
blot analysis we evaluated the expression of AR with DZNep treatment (Figure 
11B).  In both NCI H660 and 144-13 cells AR was reexpressed after only 0.1 uM 
of the drug.  The protein appears to increase with drug concentration in both cell 
lines.  However, we see more protein expression in the 144-13 cell line than the 
NCI H660 cells in contrast to what we observed at the mRNA level where there 
was more mRNA expression in the NCI H660 cells. Additionally we examined the 
effect of DZNep on global EZH2 and H3K27me3 in these cells.  There was no 
effect on EZH2 levels at 0.1 and 1 µM DZNep, whereas 5 µM DZNep caused a 
slight reduction similar to previous reports at 5 µM	  [51]. However, we did detect a 
significant reduction in H3K27me3 with treatment, also similar to previous 
studies. [44, 45] Finally, we observed a dose dependent growth inhibition in both 
cell lines (Figure 11C).  
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Materials and Methods 
Tissues and Cells 
The prostate cancer cell lines (DU145, LNCaP, PC-3, and NCI-H660) 
were obtained from the American Type Culture Collection (ATCC) and cultured 
according to their recommendations.  The xenografts samples were provided by 
the Prostate Cancer Xenograft Bank at The University of Texas MD Anderson 
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Figure 11. DZNep treatment induces AR expression in AR-SCPC cell lines. A. Quantitative RT-PCR 
showing AR mRNA expression following 72 hour DZNep treatment in 144-13 and NCIH660 cell lines.  
Fold change was calculated using the 2^ddCT method to matched untreated cell lines. B. Western blot 
analysis of the AR, EZH2, and H3K27me3 protein following 72 hour DZNep treatment in 144-13 and 
NCIH660 cell lines. GAPDH was used as a loading control. C. Percent of viable cells after 72 hours of 
DZNep treatment as compared to vehicle treated. 
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Cancer Center. Donor patient features are located in Table 2 and previously 
described [20]. 144-13 xenograft derived cell line was developed at MD 
Anderson Cancer Center. Description of this cell line will be available in a future 
publication. All cell lines were tested and certified.   
 
DNA Extraction 
The DNA was obtained via standard proteinase K and phenol–chloroform 
extraction technique and quantified on a NanoDrop 1000 spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA, USA). 
DNA was extracted from FFPE patient samples by using the Cold Spring 
Harbor protocol [52]. Briefly, xylene (cat. no. X5P-1GAL, Fisher Chemical, 
Fairlawn, NJ, USA) was used for deparaffinization followed by protease digestion 
and DNA isolation using a RecoverAll total nucleic acid isolation kit (cat. no. 
AM1975, Ambion Life Technologies Corp., Carlsbad, CA, USA). 
 
Quantitative PCR of Mouse and Human β Globins 
Quantitative PCR (qPCR) was performed on genomic DNA from each 
xenograft sample in 20-µl reactions using iTaq Supermix with ROX (Bio-Rad 
Laboratories, Hercules, CA) and TaqMan primers and probes specific for the 
human and mouse βglobin genes designed with Primer Express software 
(Applied Biosystems Life Technologies, Grand Island, NY). All probes were 
labeled with the 6-carboxyfluorescein fluorophore (6-FAM) and a custom-
synthesized nonfluorescent MGB quencher from Applied Biosystems. Primer and 
 33 
 
probe sequences are (a) murine βglobin assay, Mu-bglo-239F, 5’-
AGGCCCATGGCAAGAAAGT-3’, Mu-bglo-306R, 5’-
GCCCTTGAGGCTGTCCAA-3’, and Mu-bglo-259T (MGB probe, FAM labeled), 
5’-ATAACTGCCTTTAACGATG-3’ and (b) human βglobin assay, hu-bglo-232F, 
5’-TGAAGGCTCATGGCAAGAAA-3’, hu-bglo-285R, 5’-
GGTGAGCCAGGCCATCAC-3’, and hu-bglo-253T (MGB probe, FAM labeled), 
5’-TGCTCGGTGCCTTT-3’. The primers were used at 900 nM and the probes at 
100 nM concentrations. 
Known quantities of human and mouse DNA was used to construct a 
standard curve for both primer sets to determine the efficiency of each qPCR. 
Using the specific mouse βglobin gene, we determined cycle at threshold (Ct) 
values for each sample and a control containing 100% mouse DNA and their 
differences, delta Ct (ΔCt), using the Stratagene Mx3005P system (Agilent 
Technologies, Inc., Santa Clara, CA). Relative amounts of mouse DNA 
contamination were calculated (by using 2−ΔCt) and then converted to the 
overall percentage of mouse DNA found in each sample.  
 
MCAM Analysis 
A pool of genomic DNA extracted from normal male human peripheral 
blood mononuclear cells (PBMC) was used as a control for methylated CGI 
amplification (MCA) and coupled to CGI microarray as previously described [46, 
53]. Briefly, following digestion with SmaI and XmaI (New England BioLabs, Inc., 
Ipswich, MA), DNA was ligated to RMCA PCR adapters and amplified. Amplicons 
 34 
 
from xenograft samples were labeled with Cy5 dye and cohybridized against 
amplicons from PBMC labeled with Cy3 dye on Agilent Technologies 4 ´ 44K 
custom DNA microarrays. The 42,222 probes (corresponding to 8,321 unique 
RefSeq genes) on the array recognize SmaI/XmaI fragments predominantly 
located around gene transcription start sites (TSSs). Fluorescence signals were 
LOWESS normalized,	   [54] and trimmed averages of normalized log2 ratios were 
calculated for amplicons covered by multiple probes. Hypermethylation was 
defined as normalized log2 ratio of Cy5/Cy3 fluorescence (M values) greater than 
1.3 (equivalent to 2.5-fold and higher of xenografts/control signal intensity) on the 
basis of prior experimental data [46]. 
 
Pyrosequencing 
Validation of the methylation status of candidate genes was performed 
using bisulfite Pyrosequencing methylation analysis. Briefly, 1.5 µg of genomic 
DNA was subjected to bisulfite treatment with an EpiTect bisulfite kit (Qiagen). 
The bisulfite-treated DNA (40 ng) was amplified in a two-step PCR. A 20-µl 
reaction was carried out for each gene in 67 mmol/l Tris-HCl (pH 8.8), 16 mmol/l 
ammonium sulfate, 2 mmol/l MgCl2, 0.125 mmol/l dNTPs, 1 unit of Taq 
polymerase, and 100 nmol/l PCR primers (Table 4). TQ21 oligonucleotide (10 
nmol/l) was used as a reversible inhibitor of Taq polymerase in the first step of 
the PCR [55]. The second step of the PCR was used to label one DNA strand 
with biotin by using a universal primer tag, excluding LINE-1, which was 
biotinylated, at the 5′ end	  [56]. The second reaction contained all of the elements 
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just described plus 4.5 pmol of biotinylated universal primer (5′-biotin-
GGGACACCGCTGATCGTTTA-3′), 1 ml of PCR product from the first step, and 
new forward and reverse primers in which the reverse primer contained a 20-bp 
linker sequence (Table 3). PCR cycling conditions were 30 seconds at 95 °C, 30 
seconds at the respective annealing temperature, and 30 seconds at 72 °C for 40 
cycles. The biotinylated PCR product was bound to Streptavidin-Sepharose HP 
(GE Healthcare, Piscataway, NJ, USA), made single stranded, and purified to act 
as a template in the Pyrosequencing reaction as recommended by the 
manufacturer by using the Pyrosequencing Vacuum Prep Tool (Qiagen). Then, 
0.3-µM gene-specific Pyrosequencing primer was annealed to the purified single-
stranded PCR product, and Pyrosequencing was performed by using the PSQ 
HS 96 Pyrosequencing System (Qiagen). The raw data was analyzed using the 
allele quantitation algorithm on the Pyro Q-CpG software (Qiagen). The 
percentage methylation of each gene was computed as the average of two to 
four CpG sites. 
Table 3. Pyrosequencing Primers    
Gene  Primer Sequence 
5’ to 3’ 
Annealing 
Temperature 
Distance 
From 
Studied 
CpGs to 
SmaI Site 
Distance 
of the 
SmaI Site 
to Gene 
TSS 
ASCL2 F1 
R1 
S 
ATTGGGAATGGGGGTGGAT 
ATACCCCCCAAAACCCTCA 
AGTATTTTGTTTGTGGTT 
58 0 -477 
ASCL2 F1 
R1 
S 
GGGTGGTTTAAGATTGGTTGAGA 
CAAAAACCCCCAAACCTT 
TTTTAGGTTTTAGGAGGG  
58 -9 -86 
FOXI2 F1 
R1 
S 
GGGAGGGGAGGAAAATTGAT 
CACTAACCACCCATCCAACTTAA 
TTTATGGGTTTTGGTTT 
60 -24 -518 
FOXI2 F1 
R1 
S 
GGAGAGGTTGGATATGGTTATTT 
CTAACCCCTTCACCCACAAA 
GGTTGGATATGGTTATTTAT 
58 65 -83 
HAND 1 F1 
R1 
AGGAAAAGGGGGAGTGGTTA 
CCCATTCCCAATCCCTACTAAC 60 -56 -23 
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S GAGTGGTTATTTTAGGTTTT 
HAND 1 F1 
R1 
S 
GGGGGAGGGGATAAGGAAAA 
CCCATTCCCAATCCCTACTAAC 
GAGTGGTTATTTTAGGTTTT  
60 -56 -23 
SOX3 F1 
R1 
S 
GGTGAAAAGGTTTTGGGATTT  
CCCCCCAATTCCTACTAATTTAA 
GGGGTTTGTGGGTTA   
58 -66 172 
SOX3 F1 
R1 
R2 
S 
GGAATTGGTAGTTGGTTGTTTAGA 
CAAACCCCCAAAAACCTCAC 
AAAACCTATCTCCCATACCC  
TTTTTTTAGGAGGGTTAGT  
56 11 -673 
SOX 9 F1 
R1 
S 
AGAGGAGAAGGTATTAAAATTTTG 
AAAAAATCCCAACCAAAAAA 
AATTTATATATTTGGAAGTT 
60 101 362 
NEUROD2 F1 
R1 
S 
GTATGAGTTTGTATTGGGGGAGA   
AAAAAACAACTCCTCCCACCTTC   
TTTGTATTGGGGGAGA   
56 0 -119 
POU4F2 F1 
R1 
S 
GTATTGGGTTGGGAGTTTAGAGT 
CCACCACCCCTAAAAACACA 
GGGTTGGGAGTTTAGAG 
60 -128 -1479 
CNN3 F1 
R1 
S 
GAGGTGAGGGAAGAAGTAGG   
CCTCCTCCCCAACTCTAAACCC   
TTGTTATTGGTGTTTTAGTAG   
58 45 -333 
MAP6 F1 
R1 
S 
GAGGGATTTTATAGATTTTTTTAGGATAGT   
ACCTCCTCTTTCTTCTTATAATTCTA 
ATAGATTTTTTTAGGATAGTTTTT   
60 0 -98 
SOX8 F1 
R1 
S 
TGGATTATTTATGGGGAGGGAGT   
ACTCCTACCCTCCCTACTT 
TATGGGGAGGGAGTG   
58 -118 888 
GAS6 F1 
R1 
R2 
S 
TTGTTTTTAGGAGAGTATTTGGTAG   
ACCCTCCCTCTACTAAACTAA   
AAAAATAAAAAACAATCCCCTCC 
AGGAGAGTATTTGGTAGAA   
60 0 851 
AR F1 
R1 
F2 
R2 
S 
TAGGAAGTAGGGGTTTTTTAGGGTTAG 
ACCCAACCCACCTCCTTACCT 
GTAGGGGTTTTTTAGGGTTAGAGTTAGT 
GGGACACCGCTGATCGTTTA 
TTGTTTTTTTAAAGTTATTAGGTA  
56/60 -115 9 
BMP6 F1 
R1 
S 
TTAGGGGAGTTTTTAGTTGTTTAG 
CCTCCAAACCATTCTCCTAATA 
GTTTAGGTTAGAGAGGTGG 
60 257 -240 
NEP F1 
R1 
S 
GGGATTTGTTGAGGGGTTA 
AACACCTAAACATCCCTCC 
GATTTGTTGAGGGGTTA 
60   
CAV1 F1 
R1 
S 
TGGTTGTTTATATTGGGTATT  
AAACAACATTTTCCCTACTCT  
GTTTATATTGGGTATTTTTGTA  56 -49 -76 
GSTP1 F1 
R1 
R2 
S 
GGGAGTTAGAGGGATTTTTTAGAAGA 
CCACCTCCCAACCTTATAAAAATAAT 
CCCTCCCCCCCAATACTAAATCA 
GAGGGATTTTTTAGAAGAG 60 -111 80 
RARb F1 
R1 
S 
ATTTTTTGTTAAAGGGGGGATTAGA 
CCATACCCAAACAAACCCTACTC 
TTTGAGGATTGGGATG 60   
RASSF1 F1 
R1 
ATGTAGGGGGAGTTTGAGTTTATTGA 
CACCACCCCCCAAATAAAATC 60 -1670 -234 
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F2 
R2 
S 
GTTGGGAGAGTTGGGAAGGGT 
ACACCACCCCCCAAATAAAATC 
AGGGTYGTATTYGGTTGGA 
SLC16A12 F1 
R1 
R2 
S 
GGTTTAGGTGATAAGGGTATTTTTTAAGG 
TAGAGGGAGAGGTGGTTTAGGTGAT 
CACCCAAATTAAAATCCCAAACTC 
AAGGGTATTTTTTAAGGAAG 58 147 -5 
LINE1 F1 
R1 
S 
TTTTTTGAGTTAGGTGTGGG 
biotin-TCTCACTAAAAAATACCAAACAA 
GGGTGGGAGTGA 54   
 
 
Illumina Infinium Methylation 450k Beadchips 
DNA was extracted as described above from FFPE patient donor tumors 
and matched xenograft tissues. Genomic DNA from MDA 144-4, MDA 146-10, 
MDA 150-10, MDA 153-14, MDA 170-1 and MDA 180-14 xenograft and donor 
patient samples were run on a 0.8% agarose gel to determine the quality of the 
sample. Genome-wide methylation analysis was performed by the University of 
Southern California Epigenome Center, Los Angeles, CA on the Illumina Infinium 
Methylation 450k array. 
 
Chromatin Immunoprecipitation 
Fresh xenograft tissues were enzymatically dissociated using 10 mL of 
Accumax - Cell Aggregate Dissociation Medium (eBioscience, 00-4666-56) per 
gram of tissue, were incubated at 37 for 30 minutes under constant agitation. The 
cells were strained, washed with PBS and counted for crosslinking.  ChIP assays 
were performed by treating the cells in culture and the xenograft cells with 1% 
formaldehyde to cross-link histones to DNA. The crosslinking was stopped by 
0.125 M glycine for 5 minutes and then washed with cold PBS containing 
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protease inhibitor cocktail (Roche). The chromatin was then extracted, 
fragmented by sonication, and the lystate was immunoprecipitated using Dynal 
Protein G magnetic beads and the following antibodies: H3K4me3 (Millipore, 17-
614), H3K9ac (Millipore, 07-352), H3K9me2 (Abcam, ab1220), H3K27me3 
(Millipore, 17-622), histone H3 (Abcam, ab1791-100), and rabbit IgG (Abcam, 
ab46540). ChIP products were used for TaqMan quantitative PCR with 
oligonucleotide primers covering two regions of the AR exon 1, and positive 
controls of active Actinβ and repressed genes HBB. The fold enrichment of each 
histone modification to histone H3 was calculated using the ΔCt method. 
 
Cell Culture and Drug Treatment 
NCI-H660 and 144-13 cells were grown in RPMI-1640 with 5% FBS, 100 
ug/ml penicillin/streptomycin solution.  Cells were seeded 300,000 per 10-cm 
dish 72 hours prior to treatment. Cells were then treated with 0.1, 1, and 5 umol/L 
DZNep for 72 hrs.  The cells were harvested and counted using the Vi-CELL 
Series Cell Viability Analyzer (Beckman Coulter).  
 
Western Blotting 
Protein extracts for were prepared by homogenizing the tissues and cells 
in lysis buffer supplemented with Complete Protease (Roche). Soluble proteins 
were separated by SDS-PAGE, and transferred to PVDF membranes (BIO-
RAD). Membranes were incubated with mouse anti-EZH2 (3827-1, Epitomics), 
rabbit anti-H3K27me3 (9733s, Cell Signaling), rabbit anti-GAPDH (2118s, Cell 
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Signaling), rabbit anti-AR (n-20, Santa Cruz) and rabbit anti-histone H3 (Abcam, 
ab1791-100). The antigen-antibody complexes were detected by Luminata 
Western HRP substrate (Millipore).  
 
qPCR 
Total RNA (1 ug) was extracted using TRI-reagent (Invitrogen) followed by 
Direct-zol RNA MiniPrep Kit (Zymo) according to the manufacturer’s instructions. 
The first-strand cDNA was synthesized using the High-Capacity cDNA Reverse 
Transcription (Life Technologies, Inc.). Quantitative PCR (qPCR) was performed 
with the Universal PCR Master Mix (Applied Biosystems) and AR Taqman 
probe/primer (Hs00171172_m1, Life Technologies) using ABI Prism 7500.  
Results were obtained from 3 independent experiments in triplicate with Actin 
Beta (Hs99999903_m1, Life Technologies) as the reference gene.  Fold change 
was calculated using 2^delta delta CT method. 
 
Chart review 
The electronic medical records of the 24 patients from whose tumors the 
xenografts were obtained were retrospectively reviewed under MD Anderson’s 
IRB-approved protocol RCR06-1075 to extract the patients’ relevant 
clinicopathologic features. 
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Discussion 
This study delves into the epigenetics of CRPC in an effort to understand 
the biology of the disease, determine clinically relevant biomarkers that classify 
CRPC into subgroups and seek possible therapeutic targets. We show that DNA 
methylation profiling of CRPC xenograft tumors supports the widely accepted 
notion that CRPCs are heterogeneous. Our goal was to use DNA methylation as 
a tool to develop noninvasive biomarkers that can guide treatment decisions for 
patients with CRPC. Aberrantly hypermethylated DNA sequences can be 
detected in the peripheral circulation; therefore, differentially methylated DNA 
sequences could stratify clinically relevant tumor subtype [57, 58]. We compared 
the DNA methylation profiles of AR+ADNEO vs. AR–SCPC xenografts because 
although the AR is now known to be a central driver of a large proportion of 
CRPCs, a subset of CRPCs adopt SCPC morphological features, lose AR 
expression, and are associated with a clinically distinct and aggressive course 
despite a unique responsiveness to chemotherapy [4, 8, 59]. 
Although we did identify a small subset of methylated genes that 
distinguish AR–SCPC from AR+ADENO CRPC tissues, we did not find a 
methylated sequence that might identify the emergence of SCPC/AR– variants. 
Additionally these markers will need further validation using matched donor 
patient samples. These distinguishing methylated genes may only represent the 
heterogeneity of the disease and not the underlying biology of the SCPC 
phenotype. 
 41 
 
Our finding that the DNA methylation profiles of xenograft sublines derived 
from a single donor patient’s tumor, but grown in different mice, were more 
similar to each other than they were to the profiles of tumors derived from 
different patients suggesting that DNA methylation profiles are stable in 
xenografts and likely reflect those of patient’s tumors. This is further supported by 
our validation in patient samples of the different methylation of the GAS6 and 
CNN3 promoters, although not all genes were validated because available 
patient samples, while representative of the AR+ADNEO and AR–SCPC disease, 
they were not matched to the xenografts studied and the numbers were small.  
Moreover, approximately 20% of our CRPC tumors were characterized by lower 
levels of methylation at promoter CpG islands, similar to previous studies using 
patient tumor samples [34]. Additional studies with larger numbers of related 
donor patients’ tumor samples will be necessary to confirm that the DNA 
methylation profiles of CRPC xenografts accurately reflect the methylation 
profiles in the donor patients’ tumors.  
It must be noted that our DNA methylation profiling method identifies 
SmaI/XmaI fragments predominantly located in CpG islands around gene TSSs. 
Some authors contend that tissue- and cancer-specific differently methylated 
regions are located predominantly at DNA methylation shores, regions of low 
CpG density located near traditional CpG islands [60]. It is possible that the use 
of genome-wide methylation analysis with techniques such as bisulfite 
conversion combined with next-generation sequencing (BS-seq) will successfully 
identify differently methylated regions among the CRPC subsets. 
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Furthermore, immunohistochemical studies have shown that in most 
prostate cancer tissues (both untreated and castrate resistant), AR staining is 
heterogeneous, [61, 62] and that increased heterogeneity in AR expression is 
more frequent in less-differentiated prostate cancers [63]. Our observations and 
those of Friedlander et al. and Hill et al. raise the question of whether an 
epigenetic modifier is deregulated in the subset of tumors characterized by lower 
levels of methylation [34, 64]. Recent studies have shown that epigenetic 
modifiers are often mutated in cancers including prostate cancer [10]. The 
histone methyltransferase, MLL2, specific for H3K4 methylation, is mutated in 6% 
of CRPC along with an 8% rate of mutation or deletion in CHD1, which encodes 
an ATP-dependent chromatin-remodeling enzyme [10]. Furthermore, studies 
have shown increased levels of DNA methyltransferase 1 (DNMT1) protein and 
of DNMT3A2, DNMT3B, and EZH2 transcripts in untreated primary prostate 
tumors, relative to the levels in benign prostate tissues.  
It is clear that the androgen receptor plays a central role in prostate cancer 
and its progression. While AR is oncogenic in prostate cancer and its inhibition 
produces therapeutic responses, the loss of AR expression is associated with 
dedifferentiation of prostate cancer and an aggressive clinical behavior. 
Therefore, it is important to determine the underlying mechanism that contributes 
to it loss of expression. Epigenetic gene silencing has been implicated in multiple 
cancers, including prostate cancer, most notably DNA methylation [44]. We 
examined the promoter associated CpG island of the AR gene and determined, 
while there are some samples containing DNA methylation, AR silencing is not a 
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result of DNA methylation in CRPC.  Therefore we explored an alternate 
epigenetic pathway responsible for gene silencing and most often independent of 
DNA methylation, the polycomb repressor complex 2 which has been implicated 
in the progression of prostate cancer including the overexpression of EZH2 [35, 
38, 50, 65]. We did not detect overexpression of EZH2 in the AR-SCPC as 
compared to the AR+ADENO. Aberrant EZH2 activity is not limited to 
overexpression, but could reflect a change in activity of ncRNA binding to PRC2 
and regulating the maintenance of a repressed state [66]. PRC2 has a higher 
affinity for longer ncRNAs and thus an increase in lncRNAs that recruit PRC2 to 
the chromatin could account for the increased H3K27me3 at the AR locus 
without an increase in EZH2 protein [42, 66]. Nonetheless, we demonstrate that 
the AR gene promoter is enriched in H3K27me3 histone marks and its 
subsequent removal with DZNep results in AR mRNA and protein re-expression. 
While we have shown one mechanism responsible for AR silencing in AR-SCPC, 
it is difficult to determine, at this point, if the re-expression of AR contributes to 
the cell death we observed in vitro. DZNep was an important tool to assist us in 
establishing a functional relationship between EZH2, H3K27me3, and AR 
expression in SCPC, however its selectivity for EZH2 is poor and was found to 
globally inhibit both repressive and active histone methylation marks [44]. 
Recently, a highly selective, small-molecule inhibitor of EZH2 methyltransferase 
activity was developed by GlaxoSmith Klein, GSK126.[67] GSK126 decreases 
global H3K27me3 levels and reactivates silenced PRC2 target genes by 
competitively inhibiting the methyltransferase S-adenosyl-methionine (SAM) [67].  
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Interestingly, EZH2 could be a transcriptional coactivator of AR instead of 
the transcriptional repressor of PCR2, as it is thought to be in CRPC, through 
phosphatidylinositol 3-kinase–Akt (PI3K) pathway mediating the phosphorylation 
of EZH2 at Ser21 [65]. These investigators, however, used AR+ CRPC cell lines 
that do not represent the AR-SCPC we are studying. Therefore, while the EZH2 
function of coactivation could play a role in AR-SCPC, our data supports its 
repressor function at the AR locus. More studies are necessary to fully 
understand the epigenomic functional role in of EZH2 in AR-SCPC. 
SCPC represents a small subset of CRPC, bearing distinguishable 
morphological, clinical, genetic and epigenetic features that reflect an 
undifferentiated cellular program. Here we challenge the accepted role that AR 
activation stimulates proliferation and propose its reactivation in SCPC could 
result in tumor suppressive effects. Our findings reflect the complexity and 
diversity of epigenetic regulation in prostate cancer and underscore the 
importance for developing pharmacologic approaches for effective 
epigenetic gene reactivation. 
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